Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0032580
Disease: Adenomatous Polyposis Coli
Adenomatous Polyposis Coli 		0.010 GeneticVariation disease BEFREE Neither APC mutation status nor CHFR methylation status correlated with efficacy in the CIMP-high CRC cohort. 29069279 2018
CUI: C3266262
Disease: Multiple Chronic Conditions
Multiple Chronic Conditions 		0.010 Biomarker disease BEFREE Stabilization of HDAC1 via TCL1-pAKT-CHFR axis is a key element for NANOG-mediated multi-resistance and stem-like phenotype in immune-edited tumor cells. 30060952 2018
CUI: C3463824
Disease: MYELODYSPLASTIC SYNDROME
MYELODYSPLASTIC SYNDROME 		0.010 Biomarker group BEFREE Although a recent study showed that CHFR hypermethylation was a frequent event in acute myeloid leukemia (AML) and correlated with adverse clinical outcome, herein, we found that CHFR methylation was a rare event in patients with myeloid malignancies (including AML, chronic myeloid leukemia, and myelodysplastic syndromes), but its expression may serve as an independent prognostic biomarker in AML. 29115660 2018
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma 		0.010 AlteredExpression group BEFREE Reduced CHFR expression was associated with EGFR exon19/21 mutations in adenocarcinoma OR 0.23 (95%CI: 0.06-0.88) and male gender in squamous cell carcinoma (OR 0.46 (95%CI 0.23-0.92), p = 0.02). 25477232 2015
CUI: C0238463
Disease: Papillary thyroid carcinoma
Papillary thyroid carcinoma 		0.010 Biomarker disease BEFREE We have identified two significant epistatic gene interactions in sMTC (CHFR-AC016582.2 and C8orf37-RNU1-55P) and three in juvenile PTC (RP11-648k4.2-DIO1, RP11-648k4.2-DMGDH and RP11-648k4.2-LOXL1). 26690675 2015
CUI: C0265780
Disease: Congenital absence of lung
Congenital absence of lung 		0.010 AlteredExpression disease BEFREE CHFR expression, analyzed by RNA-seq, was classified as high vs. low based on the median CHFR expression level and correlated with the presence or absence of lung cancer specific mutations (EGFR, KRAS, ALK, MET, ERBB2, TP53, STK11, ROS1, RET, NF1, Pik3CA for adenocarcinomas and FGFR1, FGFR2, FGFR3, TP53, STK11, EGFR for squamous cell carcinomas). 25477232 2015
CUI: C1833929
Disease: THYROID CARCINOMA, SPORADIC MEDULLARY
THYROID CARCINOMA, SPORADIC MEDULLARY 		0.010 Biomarker disease BEFREE We have identified two significant epistatic gene interactions in sMTC (CHFR-AC016582.2 and C8orf37-RNU1-55P) and three in juvenile PTC (RP11-648k4.2-DIO1, RP11-648k4.2-DMGDH and RP11-648k4.2-LOXL1). 26690675 2015
CUI: C0280313
Disease: Squamous cell carcinoma of oropharynx
Squamous cell carcinoma of oropharynx 		0.010 Biomarker disease BEFREE Especially CADM1 and TIMP3 are significantly more frequently hypermethylated in HPV-positive OPSCC and CHFR in HPV-negative tumors. 25065733 2014
CUI: C1269955
Disease: Tumor Cell Invasion
Tumor Cell Invasion 		0.010 AlteredExpression phenotype BEFREE Moreover, the protein expression of Runx3 and CHFR were significantly correlated with tumor invasion depth and tumor differentiation, respectively. 20300977 2011
CUI: C0265325
Disease: Turcot syndrome (disorder)
Turcot syndrome (disorder) 		0.010 Biomarker disease BEFREE However, the p53 mutation was not related to hypermethylation of the CHFR promoter and MIN, which indicates that an abnormality in p53 occurs as an independent process from the mismatch repair deficiency in carcinogenesis. 19469003 2009
CUI: C0149782
Disease: Squamous cell carcinoma of lung
Squamous cell carcinoma of lung 		0.010 AlteredExpression disease BEFREE CHFR expression is preferentially impaired in smoking-related squamous cell carcinoma of the lung, and the diminished expression significantly harms outcomes. 18623126 2008
CUI: C0007847
Disease: Malignant tumor of cervix
Malignant tumor of cervix 		0.010 Biomarker disease BEFREE In conclusion, aberrant methylation of the CHFR gene may be useful as a molecular marker for selection of therapy for patients with cervical adenocarcinoma with a poor prognosis, and may also suggest a new therapeutic strategy of targeting CHFR in cervical cancer. 17786301 2007
CUI: C0279672
Disease: Cervical Adenocarcinoma
Cervical Adenocarcinoma 		0.010 GeneticVariation disease BEFREE In conclusion, aberrant methylation of the CHFR gene may be useful as a molecular marker for selection of therapy for patients with cervical adenocarcinoma with a poor prognosis, and may also suggest a new therapeutic strategy of targeting CHFR in cervical cancer. 17786301 2007
CUI: C0302592
Disease: Cervix carcinoma
Cervix carcinoma 		0.010 Biomarker disease BEFREE In conclusion, aberrant methylation of the CHFR gene may be useful as a molecular marker for selection of therapy for patients with cervical adenocarcinoma with a poor prognosis, and may also suggest a new therapeutic strategy of targeting CHFR in cervical cancer. 17786301 2007
CUI: C1458155
Disease: Mammary Neoplasms
Mammary Neoplasms 		0.010 Biomarker group LHGDN Altered expression of the early mitotic checkpoint protein, CHFR, in breast cancers: implications for tumor suppression. 17596595 2007
CUI: C4048328
Disease: cervical cancer
cervical cancer 		0.010 Biomarker disease BEFREE In conclusion, aberrant methylation of the CHFR gene may be useful as a molecular marker for selection of therapy for patients with cervical adenocarcinoma with a poor prognosis, and may also suggest a new therapeutic strategy of targeting CHFR in cervical cancer. 17786301 2007
CUI: C0007097
Disease: Carcinoma
Carcinoma 		0.010 PosttranslationalModification group BEFREE The methylation status of the CHFR gene was examined in primary esophageal and gastric carcinomas. 16827108 2006
CUI: C0278502
Disease: recurrent gastric cancer
recurrent gastric cancer 		0.010 PosttranslationalModification disease BEFREE DNA methylation of CHFR is not a predictor of the response to docetaxel and paclitaxel in advanced and recurrent gastric cancer. 16475678 2006
CUI: C0079773
Disease: Lymphoma, T-Cell, Cutaneous
Lymphoma, T-Cell, Cutaneous 		0.010 Biomarker disease BEFREE In addition, the promoters of the selected tumor suppressor genes p73 (48%), p16 (33%), CHFR (19%), p15 (10%), and TMS1 (10%) were hypermethylated in CTCL. 15897551 2005
CUI: C0014859
Disease: Esophageal Neoplasms
Esophageal Neoplasms 		0.010 AlteredExpression group BEFREE We report here that a significant proportion of human esophageal cancer has loss of expression of Chfr gene. 12376479 2002
CUI: C0014859
Disease: Esophageal Neoplasms
Esophageal Neoplasms 		0.010 AlteredExpression group LHGDN We report here that a significant proportion of human esophageal cancer has loss of expression of Chfr gene. 12376479 2002
CUI: C0152018
Disease: Esophageal carcinoma
Esophageal carcinoma 		0.010 AlteredExpression disease BEFREE We report here that a significant proportion of human esophageal cancer has loss of expression of Chfr gene. 12376479 2002
CUI: C0546837
Disease: Malignant neoplasm of esophagus
Malignant neoplasm of esophagus 		0.010 AlteredExpression disease BEFREE We report here that a significant proportion of human esophageal cancer has loss of expression of Chfr gene. 12376479 2002
CUI: C0023467
Disease: Leukemia, Myelocytic, Acute
Leukemia, Myelocytic, Acute 		0.020 AlteredExpression disease BEFREE Our findings revealed that lower CHFR expression was independently associated with unfavorable prognosis in AML. 29115660 2018
CUI: C0280100
Disease: Solid Neoplasm
Solid Neoplasm 		0.020 PosttranslationalModification phenotype BEFREE CHFR acts as a tumor suppressor gene, which is frequently inactivated caused by its promoter hypermethylation in various solid tumors. 29115660 2018